Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 14 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

79%

11 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 4
9(69.2%)
Phase 3
2(15.4%)
Phase 1
2(15.4%)
13Total
Phase 4(9)
Phase 3(2)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (14)

Showing 14 of 14 trials
NCT07342257Phase 1Completed

SYN023 With Rabies Vaccine in Healthy Pediatric Subjects

Role: collaborator

NCT06033807Recruiting

Active Screening of Latent Tuberculosis Infection in School Contacts of Active Tuberculosis Patients

Role: collaborator

NCT05890521Phase 4Unknown

Safety Study of COVID19 Vaccine on the Market

Role: collaborator

NCT04091880Phase 4Completed

Evaluation of the Safety and Immunogenicity of Simultaneously Administration of EV71 Vaccine and Influenza Vaccine

Role: collaborator

NCT05480436Phase 4Unknown

Immunogenicity and Safety of BBIBP-Corv Coadministered With PPV23 and IIV4 in Hemodialysis Population

Role: collaborator

NCT04559204Phase 4Completed

Evaluation of Safety and Immunogenicity of Combined Immunization of PPV23 and IIV4

Role: collaborator

NCT05453487Phase 4Unknown

Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered With Rabies Vaccine

Role: collaborator

NCT05065879Phase 4Completed

Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes

Role: collaborator

NCT05104333Phase 4Unknown

Evaluation of Immunogenicity, Safety and Antibody Persistence of COVID-19 Booster Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes

Role: collaborator

NCT05104437Phase 4Unknown

Evaluation of Immunogenicity, Safety and Antibody Persistence of COVID-19 Booster Vaccine (Produced in Wuhan) in Patients With Hypertension and/or Diabetes

Role: collaborator

NCT05065892Phase 4Unknown

Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Wuhan) in Patients With Hypertension and/or Diabetes

Role: collaborator

NCT02919293Phase 1Unknown

Immunogenicity and Safety of Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine in Infants 2 to 5 Months of Age

Role: collaborator

NCT01108614Phase 3Unknown

Injecting Drug Use Community Intervention Trial

Role: collaborator

NCT01068015Phase 3Unknown

(Men Who Have Sex With Men) MSM Community Intervention Trial

Role: collaborator

All 14 trials loaded